1. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Issue 9 (2nd September 2021) Authors: Song, Yuqin; Guo, Ye; Huang, Huiqiang; Li, Wei; Ke, Xiaoyan; Feng, Jifeng; Xu, Wei; Miao, Harry; Kinley, Judith; Song, Gregory; Dai, Yi; Wang, Hui; Zhu, Jun Journal: Expert review of hematology Issue: Volume 14:Issue 9(2021) Page Start: 867 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens. (28th June 2020) Authors: Suri, Ajit; Mould, Diane R.; Song, Gregory; Kinley, Judith; Venkatakrishnan, Karthik Journal: Journal of clinical pharmacology Issue: Volume 60:Number 12(2020) Page Start: 1585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Issue 10 (October 2018) Authors: Locatelli, Franco; Mauz-Koerholz, Christine; Neville, Kathleen; Llort, Anna; Beishuizen, Auke; Daw, Stephen; Pillon, Marta; Aladjidi, Nathalie; Klingebiel, Thomas; Landman-Parker, Judith; Medina-Sanson, Aurora; August, Keith; Sachs, Jessica; Hoffman, Kristen; Kinley, Judith; Song, Sam; Song, Greg... Journal: Lancet Issue: Volume 5:Issue 10(2018) Page Start: e450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗